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 yoepithelial cells have an important role in salivary gland tumor development, contributing
to a low grade of aggressiveness of these tumors. Normal myoepithelial cells are known by
their suppressor function presenting increased expression of extracellular matrix genes
and protease inhibitors. The importance of stromal cells and growth factors during tumor
initiation and progression has been highlighted by recent literature. Many tumors result
from the alteration of paracrine growth factors pathways. Growth factors mediate a wide
variety of biological processes such as development, tissue repair and tumorigenesis, and
also contribute to cellular proliferation and transformation in neoplastic cells. Objectives:
This study evaluated the expression of fibroblast growth factor-2 (FGF-2), transforming
growth factor β-1 (TGFβ-1), platelet-derived growth factor-A (PDGF-A) and their respective
receptors (FGFR-1, FGFR-2, TGFβR-II and PDGFR-α) in myoepithelial cells from pleomorphic
adenomas (PA) by in vivo and in vitro experiments. Material and Methods: Serial sections
were obtained from paraffin-embedded PA samples obtained from the school’s files.
Myoepithelial cells were obtained from explants of PA tumors provided by surgery from
different donors. Immunohistochemistry, cell culture and immunofluorescence assays were
used to evaluate growth factor expression. Results: The present findings demonstrated
that myoepithelial cells from PA were mainly positive to FGF-2 and FGFR-1 by
immunohistochemistry and immunofluorescence. PDGF-A and PDGFR-α had moderate
expression by immunohistochemistry and presented punctated deposits throughout
cytoplasm of myoepithelial cells. FGFR-2, TGFβ-1 and TGFβR-II were negative in all samples.
Conclusions: These data suggested that FGF-2 compared to the other studied growth
factors has an important role in PA benign myoepithelial cells, probably contributing to
proliferation of these cells through the FGFR-1.
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INTRODUCTION
Myoepithelial cells are important components
of benign and malignant salivary gland tumors
contributing to histological diversity and low grade
pattern of these tumors2,5,6. It is known that
normal myoepithelial cells have an important role
as tumor suppressors, being therefore a defense
against cancer progression5,42.
Pleomorphic adenoma (PA) is the most
common type of benign salivary gland tumor in
both major and minor salivary glands being a
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good source of myoepithelial cells, different from
breast gland tumors4.
Several growth factors are involved in the
initiation and progression of tumors, as autocrine
and paracrine mediators. These include the family
of fibroblast growth factor (FGF), transforming
growth factor β (TGFβ) and platelet-derived
growth factor (PDGF), which are predominant
stimulators of cell proliferation and present in
the pathogenesis of many tumors, including
salivary gland tumors12,21,26,27,32,43,48.
The FGF2 also referred as basic FGF (FGFb),
is a member of 22 polypeptides localized in the
extracellular matrix (ECM), cytoplasm and
nucleus of the cells11,21. Several functions are
attributed to this growth factor such as: mitogenic
function, cell differentiation, angiogenesis,
phenotypic transformation3,47, and survival of
tumor and stem cells13,14,33,46. In normal
myoepithelial cell and myoepithelial-like cell lines
of mammary gland, FGF2 is considered to be a
product derived from these cells19,37, and its
enhanced expression is associated to the
differentiation of epithelial cells into
myoepithelial-like phenotype19. The FGF
transmembrane receptors FGFR-1 or Flg and
FGFR-2 or Bek are required in the development
of many tissues, including salivary gland15,17,28,31.
The PDGF is a family of five cationic homo-
and heterodimer isoforms, considered a product
of platelet cells synthesized by different cell
types1. Its synthesis is in response to external
stimuli, such as exposure to low oxygen
tension1,12 or stimulation by other cytokines and
growth factors1. It has an important role as an
autocrine growth factor for PDGF receptor-
positive tumor cells16,38, but it is poorly elucidated
in salivary gland tumors. This factor exerts its
biologic effects by inducing homo- or
heterodimeric complexes of α- and β- tyrosine
kinase receptors, PDGFR-α and PDGFR-β1,16. Both
receptors can activate signal transduction
pathways, stimulating cell growth and
angiogenesis, whereas activation of the PDGFR-
α inhibits and stimulates chemotaxis of certain
cell types1.
TGFβ is a highly pleiotropic cytokine present
in mammals that modulates proliferation,
differentiation, apoptosis, adhesion, and
migration of various cell types and favors the
production of ECM proteins36. Production of TGFβ
is part of the regulatory mechanism controlling
the growth and differentiation of both non-
malignant and malignant cells34. TGFβ-1 initiates
intracellular signaling by two types of
transmembrane receptors known as type I
(TGFβRI) and type II (TGFβRII) receptors7,34.
Based on the role of growth factors in tumors,
the aim of this study was to analyze the
expression of FGF-2, TGFβ-1, PDGF-A, and their
respective receptors (FGFR-1, FGFR-2, TGFβR-II
and PDGFR-α) on benign myoepithelial cells from
PA in vivo by immunohistochemistry and also in
vitro by immunofluorescence.
Case Gender Age (years) Localization
1 Male 20 Upper Lip
2 Female * Upper Lip
3 Female 30 Upper Lip
4 Female 22  Submandibular region
5 Female 23 Parotid
6 Female 28 Hard Palate
7 Female 56 Upper Lip
8 Female 25 Upper Lip
9 Female 36 Hard Palate
10 Female 25 Upper Lip
11 Female 28 Hard Palate
12 Female 39 Palate
*Not available.
Figure 1- Sex, age and localization of the pleomorphic adenoma
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MATERIAL AND METHODS
Immunohistochemistry
The research protocol was approved by the
Research Ethics Committee of São Leopoldo
Mandic Institute and Research Center, Campinas,
Brazil (Protocol # 07/124).
Twelve cases of PA were retrieved from the
files of the Department of Pathology, São
Leopoldo Mandic Institute and Research Center,
Campinas, Brazil (Figure 1).
Three-micrometer-thick serial sections were
obtained from paraffin-embedded samples and
the dewaxed sections were processed to antigen
retrieval. Endogenous peroxidase was blocked
by incubation with 3% hydrogen peroxide and
methanol (1:1). After washing, sections were
incubated with primary polyclonal antibodies
(Figure 2). Signal detection was performed using
the DAKO EnVision Peroxidase (DakoCytomation,
Carpentaria, CA, USA), followed by a
diaminobenzidine chromogen solution and
counterstaining with Mayer’s hematoxylin. The
reactions were executed by Dako Autostainer Plus
(DakoCytomation).
The labeled sections were qualitatively
evaluated by two examiners observing cytoplasm
and/or nuclear positive stained cells. The
immunohistochemical reaction was evaluated
according to the extent of positive staining using
the following score, by percentage: 0, staining
from 0 to 10%; 1, staining from 10 to 25%; 2,
staining from 25 to 50%; 3, staining up to 50%.
Cell Culture
Myoepithelial cells were obtained from
explants of PA tumors (cases 4, 5 and 8) provided
by surgery from different donors. This part of
the study was conducted after approval of the
Research Ethics Committee of São Leopoldo
Mandic Institute and Dental Research Center,
Campinas, Brazil (Protocol # 2009/0014).
The obtained cells were cultured in Dulbecco’s
modified Eagle medium (DMEM, Sigma-Aldrich
Inc., St Louis, MO, USA) supplemented by 1%
antimycotic-antibiotic solution (10000 units
penicillin, 10 mg streptomycin and 25 µg
amphotericin B per mL in 0.9% sodium chloride;
Sigma®), containing 10% of fetal bovine serum
(FBS; Gibco, Buffalo, NY, USA), plated in 60-mm
diameter plastic culture dishes and incubated
under standard cell culture conditions (37°C,
100% humidity, 95% air, and 5% CO
2
). When
the cells reached confluence, they were detached
with 0.05% trypsin and subcultured at a density
of 20,000 cells/well (~110 cells/mm2). The cells
were used at subculture levels 3 or 4, and the
cells were characterized using anti-α smooth
muscle actin, anti-calponin and anti-vimentin
(Figure 4 A-C). CK7 was also analyzed (Figure 4
D). The primary polyclonal antibodies are
described at Figure 2.
Antibody Immunohistochemical Immunofluorescence Host Sources
Dilution Dilution
FGF-2 1:100 1:50 Rabbit St. Cruz Biotechnology1
FGFR-1 1:150 1:100 Rabbit St. Cruz Biotechnology1
FGFR-2 1:50 1:50 Rabbit St. Cruz Biotechnology1
TGFβ-1 1:200 1:100 Rabbit St. Cruz Biotechnology1
TGFβR-II 1:50 1:50 Rabbit St. Cruz Biotechnology1
PDGF-A 1:50 1:50 Rabbit St. Cruz Biotechnology1
PDGFR-α 1:100 1:50 Rabbit St. Cruz Biotechnology1
Vimentin 1:300 1:300 Mouse Dako2
α-smooth 1:300 1:50 Mouse Dako2
muscle actin
Calponin 1:50 1:20 Mouse Dako2
CK7 1:100 1:50 Mouse Dako2
1
 Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA. 2DakoCytomation, Carpentaria, CA, USA.
Figure 2- Primary polyclonal antibodies
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Immunofluorescence
Cells grown on coverslips were fixed in
methanol for 6 min at 20°C, rinsed in PBS
followed by blocking with 1% bovine albumin in
phosphate buffer saline (PBS) for 30 min at room
temperature. The primary polyclonal antibodies
are described at Figure 2. Control staining
reaction was performed using PBS as non-
immune IgGs at the same dilution used for the
primary antibody. The secondary antibodies used
were biotinylated anti-rabbit and anti-mause IgG
(Vector Laboratories Inc, Burlingame, CA, USA).
Fluorescein-streptavidin conjugated (Vector)
were used for the second step. After washing,
preparations were mounted using Vectashield
DAPI-associated (4'-6-diamidino-2-phenylindole)
Case FGF-2 FGFR-1 FGFR-2 TGFβ-1 TGFβR-2 PDGF-A PDGFR-α
1 3 2 0 0 0 0 0
2 3 3 0 0 0 0 1
3 3 3 0 0 0 1 1
4 3 2 1 0 0 1 1
5 3 3 1 0 0 1 1
6 3 2 0 0 0 0 1
7 3 2 0 0 0 0 1
8 3 3 0 0 0 1 1
9 3 3 2 0 0 1 1
10 3 3 1 0 0 1 1
11 3 3 1 0 0 0 0
12 3 3 1 0 0 0 0
Score 0: 0- 10% of positive cells; Score 1: 10- 25% of positive cells; Score 2: 25- 50% of positive cells; Score 3: up to 50%
of positive cells.
Figure 3- Immunohistochemical expression of FGF-2, PDGF-A, TGFβ-1 and respective receptors in myoepithelial cells of
pleomorphic adenoma
Figure 4- Immunostaining for α-AML (A), calponin (B), vimentin (C) and CK7 (D) in myoepithelial cells from PA. Observe
that some myoepithelial cells were negative for α-AML (A) and calponin (B), but all cells were immunoreactive for vimentin
(C). Rare cells expressed CK-7 (D). Nuclei stained with DAPI appear in blue. Original magnification- A-D: ×200
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(Vector) and observed on a Zeiss Axioskop 2
conventional fluorescence microscope (Zeiss, Carl
Zeiss MicroImaging, Oberköchen, Germany)
equipped with ×63 Plan Apochromatic 1.4NA and
×100 Plan Apochromatic 1.4NA objectives in
standard conditions (Zeiss®).
RESULTS
Immunohistochemistry
FGF-2 was strongly expressed in most
cytoplasms and nuclei of PA myoepithelial cells
(Figure 5A and B). FGFR-1 was immunoreactive
in some cytoplasm and nucleus (Figure 5C). On
the other hand, there was no FGFR-2 expression
(Figure 5D) except for focal cells in two cases
(data not shown). PDGF-A immunostaining was
Figure 5- Immunohistochemical expression of FGF-2 (A and B), FGFR-1 (C), FGFR-2 (D), PDGF-A (E), PDGF-α (F), TGF-
β (G) and TGFβR-II (H). Observe that most myoepithelial cells were strongly positive for FGF-2 (A and B), while for FGFR-
1 only some cells were immunostained (C). No expression was observed for FGFR-2 (D). PDGF-A (E) and PDGFR-α (F)
were moderately immunoreactive in some cytoplasm and nuclei of myoepithelial cells. No reaction for TGF-β (G) and
TGFβR-II (H) was observed. Original magnification- A-H: ×400
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moderate in the cytoplasm and in some nuclei of
myoepithelial cells (Figure 5E) with the same
pattern of immunoreaction for PDGFR-α (Figure
5F). TGFβ-1 (Figure 5G) and TGFβR-2 were
negative in all studied cases (Figure 5H).
Figure 3 summarizes the expression of the
growth factors and their receptors.
Immunofluorescence
FGF-2 was immunoexpressed in all
myoepithelial cells and was detected as a diffuse
reticular network throughout the cytoplasm
(Figure 6A). FGFR-1 immunostaining all
myoepithelial cells, mainly in the nucleus (Figure
6B). PDGF-A (Figure 6C) and PDGFR-α (Figure
6D) were immunoexpressed as punctate deposits
throughout the cytoplasm. No immunoreactivity
for FGFR-2, TGFβ-1 and TGFβR-II was observed
in the myoepithelial cell cultures (data not
shown).
DISCUSSION
The present findings demonstrated that FGF-
2 and FGFR-1 were the main expressed factors
in myoepithelial cells from PA by in vivo and in
vitro experiments compared with the FGFR-2,
PDGF-A, PDGFR-α, TGFβ-1 and TGFβR-II.
The benign myoepithelial cell has an important
role in salivary gland tumor development. Tumors
composed of these cells have low
aggressiveness2. It is known that normal
myoepithelial cells have a suppressor function,
presenting increased expression of ECM genes
and protease inhibitors and reduced expression
of angiogenic factors and proteinases5,42.
Pleomorphic adenoma is reported to be a great
source of myoepithelial cells4. In the present
study, this evidence was confirmed by the in vitro
characterization of myoepithelial cell line from
PA, which presented mainly positive myoepithelial
markers (anti-α smooth muscle actin, anti-
calponin and anti-vimentin) and negative or rare
positive cells for luminal markers (CK-7 and AE1/
AE3). In addition, in the present study growth
factors that promote the outgrowth of epithelial
cells have not been added to the cultures.
In the present study, FGF-2 was strongly
expressed in most cytoplasm and nucleus of PA
myoepithelial cells by immunohistochemistry. It
is known that FGF-2 is an important growth factor
involved in cell proliferation9 and differentiation10.
Figure 6- Immunostaining for FGF-2 (A), FGFR-1 (B), PDGF-A (C) and PDGFR-α (D) in myoepithelial cells from PA. FGF-
2 was expressed as a reticular network in all cytoplasm (A). FGFR-1 was immunoreactive mainly in the nuclei of the cells
(B). PDGF-A (C) and PDGFR-α(D) were immunoexpressed as punctate deposits throughout the cytoplasm. Nuclei stained
with DAPI appear in blue. Original magnification- A-D: ×400
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It can be found in ECM, cytoplasm and nucleus
of the cells11,29 activating signal pathways by
transmembrane receptors, acting as an autocrine
and paracrine factor5,26,27.
The immunofluorescence assay confirmed the
reactivity of myoepithelial cells to FGF-2, mainly
in the cytoplasm exhibiting a diffuse reticular
network. Taverna, et al.45 (2008) demonstrated
that intracellular trafficking of endogenous FGF-
2, destined for secretion into the ECM, is related
with the presence of actin filament. This might
explain the reticular and diffuse expression
pattern of this growth factor throughout the
cytoplasm. Myoepithelial cells from PA were
positive to FGFR-1, by immunohistochemistry
assay, in both cytoplasm and nucleus. Nuclear
immunoexpression was mainly evident in the in
vitro assay.
In general, the majority of growth factor
receptors play their role in signal transduction at
the cell surface, which activates ligand-dependent
intracellular signaling networks35. However, some
studies have demonstrated a different pathway
involving nuclear translocation after
internalization8,18,49.
It is demonstrated that FGFR-1, which is is
also a transmembrane protein, translocate to the
nucleus after ligand stimulation that is mediate
by importin-α and E-cadherin8,35,41, playing a role
in the regulation of cell cycle. In malignant
salivary gland tumors, the overexpression of FGF-
2 and FGFR-1 facilitates neoplastic
progression21,27. FGFR-2 expression was negative
in all myoepithelial cells both in in vivo and in
vitro results. In the literature, FGFR-2 has been
considered as risk factor in breast cancer24 and
contributes to cell growth, invasiveness, motility
and angiogenesis22,25. The absence of FGFR-2 in
PA is in accordance with the benign behavior of
this tumor.
In the present study, no immunoreactivity for
TGFβ-1 and TGFβR-II was observed in PA and
neither in the myoepithelial cell cultures, which
is in accordance with the results of Kusafuka, et
al.20 (2001).
Numerous studies have demonstrated that
TGFβ-1 may strongly inhibit growth and induce
apoptosis in nontransformed cells. In malignant
tumors, the loss of TGFβ-1 is associated with
tumor immunosurveillance39. In established
tumors, TGFβ-1 exerts a favorable effect for the
survival, progression and metastasis mainly
related with malignant tumors30,40.
PDGF-A immunohistochemical expression was
moderate in the cytoplasm and nucleus of some
myoepithelial cells with the same pattern of
immunoreaction for PDGFR-α. This factor has a
paracrine function in PDGFR positive cells and
stimulates the stroma to up-regulate FGF-2,
promoting angiogenesis and cell proliferation in
neoplastic cells32.
PDGF is related to malignant transformation,
as previously demonstrated. Demasi, et al.12
(2008) observed that PDGF-A and PDGFR-α were
slightly detected in remnant pleomorphic
adenoma presented in CXPA, but they were
collectively highly expressed as soon as the
malignant phenotype was achieved and they were
kept on elevated levels during the progression
to the advanced stages of CXPA.
We have also observed that PDGF-A and its
receptor, by immunofluorescence, were present
as punctate deposits throughout the cytoplasm.
The punctate pattern of PDGF-A and PDGFR-α
expression is justified because they regulate
intracellular signal transduction by internalization
to cytoplasm cell via caveolae endocytosis23.
Caveolae is flask-shaped plasma membrane
invaginations that mediate endocytosis and
transcytosis of plasma macromolecules, and also
growth factors as PDGF, present in cytoplasm of
cells as a punctate pattern23,44.
The results obtained both in vivo and in vitro
assays were very similar, demonstrating that FGF-
2, compared to the other studied growth factors,
is an important factor in myoepithelial cells of
PA, probably contributing to PA proliferation
through the FGFR-1.
CONCLUSION
FGF-2 may have an important role in PA
myoepithelial cell proliferation mediated by FGFR-
1 receptor.
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